Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CANbridge Pharmaceuticals Inc. ( (HK:1228) ) has provided an announcement.
CANbridge Pharmaceuticals Inc. announced the closure of its register of members in preparation for an extraordinary general meeting (EGM) scheduled for December 4, 2025. This meeting is significant for shareholders as it determines their eligibility to attend and vote, impacting the company’s governance and strategic decisions. The closure period is from December 1 to December 4, 2025, and shareholders must ensure their shares are registered by November 28, 2025, to participate. This announcement underscores the company’s commitment to structured shareholder engagement and could influence its operational and strategic direction.
The most recent analyst rating on (HK:1228) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.
More about CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company incorporated in the Cayman Islands, focusing on developing and commercializing innovative therapies for rare diseases and targeted cancers. The company operates in the pharmaceutical industry, aiming to address unmet medical needs in these specialized markets.
Average Trading Volume: 5,927,262
Technical Sentiment Signal: Buy
Current Market Cap: HK$955.2M
For detailed information about 1228 stock, go to TipRanks’ Stock Analysis page.